AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.

Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or ...

DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

Arkansas’ own statistics show much work to be done. Per a 2023 press release from the Arkansas Department of Health, nearly ...

The Breast Reconstruction Market has witnessed remarkable advancements in recent years, driven by medical innovations, a ...

A combination of two existing chemotherapy drugs has been used to fight bladder cancer successfully for the first time in Singapore. This new union of the two “off-label” drugs – gemcitabine and ...

Bengaluru: For Latha (name changed), a 37-year-old woman diagnosed with breast cancer in April 2024, the news of her illness ...

Radiotherapy has been a cornerstone of cancer treatment for decades, offering a targeted approach to treat tumors. Yet, as ...

Dr. Taylor Theunissen performs autologous breast reconstruction procedures in Baton Rouge, offering cancer survivors natural tissue-based options for post-mastectomy reconstruction with improved ...

They were used on five patients, and four of them are now either in remission or cancer-free. Read more at straitstimes.com.